Kinderhook, N.Y., January 26, 2021 – American Bio Medica Corporation (OTCQB: ABMC), a US-based manufacturer of accurate, cost-effective immunoassay test kits, issued a statement today regarding President Joe Biden’s executive order directing the federal government to increase its purchases of goods Made in America.
Chief Executive Officer Melissa A. Waterhouse stated, “As we have stated a number of times over the past several years, it has been difficult for ABMC to compete in our industry and secure government contracts due to lower priced drug tests made outside of the United States. We are pleased that President Biden is taking steps to change that and at a minimum, level the playing field for US manufacturers; especially small businesses like ABMC. One area of particular interest for us is the administration’s pledge to crack down on false advertising on “Made in America” products; this is an area that has been especially challenging for ABMC as we have continued to manufacture of our drug tests 100% in the United States while others have moved those operations entirely or partly off-shore.”
Waterhouse continued, “In addition to the drug testing products we make, ABMC has the ability to manufacture tests for many medical conditions, viruses and diseases using lateral flow technology in our FDA registered and ISO certified facilities in Kinderhook, New York and Logan Township, New Jersey. We currently manufacture tests to detect respiratory syncytial virus (RSV) and malaria. We have manufactured products to detect fetal amniotic rupture, HIV, Syphilis, and Tuberculosis, as well as numerous other tests. We are hopeful that this order will support our efforts, already underway, to expand our contract manufacturing business.”
To place an order or to learn more about ABMC’s manufacturing capabilities; customers can call (800) 227-2343, or (518) 758-8158 outside the United States or, contact the company via email at firstname.lastname@example.org.
For more information on ABMC or its testing products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse, and distributes a rapid test to detect Covid-19 antibodies, a RT-PCR test to detect Covid-19 and a rapid Covid-19 antigen test.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, future sales and profit levels of the rapid antibody test and RT-PCR test for Covid-19 that we are distributing, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2019, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.